Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Zogenix, Inc.

UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases that have significant unmet needs. This includes discovery, development, and delivery of therapies with a culture of care around patient value.

msh id	COM:ZOGENIX
symbol	ZGNX
name	Zogenix, Inc.
homepage url	https://www.zogenix.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	327
crunchbase url	-
linkedin url	-
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.26
growth cost of revenue	7.92
growth depreciation and amortization	0.73
growth ebitda	0.07
growth ebitda ratio	0.84
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	4.87
growth gross profit ratio	-0.02

COM:ZOGENIX

UCB

Last Close

26.68

01/01 00:00

Volume Today

11.25M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	303.9M
cost of revenue	303.9M
depreciation and amortization	9.46M
ebitda	-202.58M
ebitda ratio	-2.48
eps	-4.24
eps diluted	-4.24
operating expenses	299.07M
operating income	-212.03M
operating income ratio	-2.6

accounts receivables	-6.32M
capital expenditure	-83K
cash at beginning of period	166.92M
cash at end of period	101.18M
inventory	5.49M
working capital ttm	256.87M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-